Use of biosimilars in paediatric inflammatory bowel disease: A position statement of the ESPGHAN paediatric IBD porto group

ESPGHAN Paediatric IBD Porto Group

Research output: Contribution to journalArticlepeer-review

Abstract

Because the patents for biopharmaceutical monoclonal antibodies have or soon will expire, biosimilars are coming to the market. This will most likely lead to decreased drug costs and so easier access to these expensive agents. Extrapolation, however, of the limited available clinical data from adults with rheumatologic diseases to children with inflammatory bowel disease (IBD) should be done with caution and needs some considerations. Postmarketing surveillance programs for efficacy, safety, and immunogenicity should become mandatory in children with IBD using biosimilars, as for all biological drugs.

Original languageEnglish
Pages (from-to)503-508
Number of pages6
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume61
Issue number4
DOIs
StatePublished - 1 Oct 2015

Funding

FundersFunder number
AbbVie
Celgene
Ferring
Merck
Pfizer
Shire

    Keywords

    • Biosimilar
    • Inflammatory bowel disease
    • Infliximab
    • Paediatric
    • Position paper

    Fingerprint

    Dive into the research topics of 'Use of biosimilars in paediatric inflammatory bowel disease: A position statement of the ESPGHAN paediatric IBD porto group'. Together they form a unique fingerprint.

    Cite this